Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors.

Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors.

Item
http://www.wikidata.org/entity/Q33414445
Radotinib Induces Apoptosis of CD11b+ Cells Differentiated from Acute Myeloid Leukemia CellsA Cell-Based Assay for Measuring Endogenous BcrAbl Kinase Activity and Inhibitor ResistanceA phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemiasRadotinib is an effective inhibitor of native and kinase domain-mutant BCR-ABL1.European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.How I treat newly diagnosed chronic myeloid leukemia in 2015.Update on emerging treatments for chronic myeloid leukemia.Optimization of radotinib doses for the treatment of Asian patients with chronic myelogenous leukemia based on dose-response relationship analyses.Radotinib and its clinical potential in chronic-phase chronic myeloid leukemia patients: an update.Radotinib in the treatment of chronic phase chronic myeloid leukemia patients.Comment on "efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors".Targeting c-KIT (CD117) by dasatinib and radotinib promotes acute myeloid leukemia cell death.Baseline BCR-ABL1 transcript type of e13a2 and large spleen size are predictors of poor long-term outcomes in chronic phase chronic myeloid leukemia patients who failed to achieve an early molecular response after 3 months of imatinib therapy.Current paradigms in the management of Philadelphia chromosome positive acute lymphoblastic leukemia in adults.Radotinib-induced lentiginosis: a report of an adverse cutaneous reaction associated with a tyrosine kinase inhibitor.Determination of a radotinib dosage regimen based on dose-response relationships for the treatment of newly diagnosed patients with chronic myeloid leukemia.The c-Abl inhibitor, Radotinib HCl, is neuroprotective in a preclinical Parkinson's disease mouse model.
P2860

Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors.

Item
http://www.wikidata.org/entity/Q33414445
description
2014 nî lūn-bûn
@nan
2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
Efficacy and safety of radotin ...... L1 tyrosine kinase inhibitors.
@ast
Efficacy and safety of radotin ...... L1 tyrosine kinase inhibitors.
@en
type
label
Efficacy and safety of radotin ...... L1 tyrosine kinase inhibitors.
@ast
Efficacy and safety of radotin ...... L1 tyrosine kinase inhibitors.
@en
prefLabel
Efficacy and safety of radotin ...... L1 tyrosine kinase inhibitors.
@ast
Efficacy and safety of radotin ...... L1 tyrosine kinase inhibitors.
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P577
P698
P921
P932
P356
P1433
P1476
Efficacy and safety of radotin ...... L1 tyrosine kinase inhibitors.
@en
P2093
P2860
P304
P31
P356
10.3324/HAEMATOL.2013.096776
P433
P478
P577
P698
P921
P932